February 25, 2022
Baudax Bio Announces Proposed Public Offering of Securities
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical…
Pharmaceuticals, Biotechnology and Life Sciences
Author: GlobeNewswire
February 25, 2022
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using…
February 25, 2022
DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022
Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3,…
February 25, 2022
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…
February 25, 2022
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE)…
February 25, 2022
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study…
February 25, 2022
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended…
February 25, 2022
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides to 2022 Total Revenues of…
February 25, 2022
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids…
February 24, 2022
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))…